All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the International Symposium on Hodgkin Lymphoma (ISHL) 2022 meeting, the Lymphoma Hub spoke with Irene Biasoli, Federal University of Rio de Janeiro, Rio de Janeiro, BR. We asked, What does data from the Brazilian Prospective Hodgkin Lymphoma Registry tell us about outcomes for older patients with Hodgkin lymphoma?
What does data from the Brazilian Prospective HL Registry tell us about outcomes for older patients?
Biasoli describes the Brazilian Prospective Hodgkin Lymphoma Registry and comments on the information gathered from older patients in the registry about treatment patterns, survival rates, and the impact of socio-economic status.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
A new analytical tool to assess the adverse event burden in older patients with CLL treated with bendamustine plus rituximab or ibrutinib regimens: based on the Alliance A041202 trial
Chronic lymphocytic leukemia (CLL) is a disease that is common in...
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
Stefano Luminari talks about the high incidence of DLBCL in elderly patients.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox